Human papillomavirus (HPV) Associated Cancer Pipeline Insights 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "Human papillomavirus (HPV) Associated Cancer Pipeline Insight, 2025," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Human papillomavirus (HPV) Associated Cancer pipeline landscape. It covers the Human papillomavirus (HPV) Associated Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Human papillomavirus (HPV) Associated Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Human papillomavirus (HPV) Associated Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Human papillomavirus (HPV) Associated Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Human papillomavirus (HPV) Associated Cancer Pipeline Report
• In July 2025, Marengo Therapeutics Inc. announced a Phase 1/2 study consists of two parts: Phase 1 Dose Escalation and Phase 2 Dose Expansion. In Phase 1 Dose Escalation, STAR0602 will be administered intravenously in participants with advanced solid tumors to assess safety/tolerability profile of STAR0602 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of STAR0602.
• In July 2025, Theravectys S.A. announced a Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants With HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer.
• DelveInsight's Human papillomavirus (HPV) Associated Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Human papillomavirus (HPV) Associated Cancer treatment.
• The leading Human papillomavirus (HPV) Associated Cancer Companies such as Turnstone Biologics, Advaxis, AstraZeneca, VLP The Vaccines Company SL, Voltron Therapeutics Inc, Rubius Therapeutics, Inovio Pharmaceuticals, Bristol-Myers Squibb, Precigen Inc, Privo Technologies, ViciniVax BV, Avalia Immunotherapies, BlueSky Immunotherapies, Cellid Co Ltd, Cue Biopharma, Cullinan Oncology, Genexine, EyeGene, Hookipa Pharma, Immunomic Therapeutics, ISA Pharmaceuticals BV, SQZ Biotechnologies and others.
• Promising Human papillomavirus (HPV) Associated Cancer Pipeline Therapies such as Aldesleukin, MEDI0457, RO5217790, Pembrolizumab, INO-3107, CELLECTRATM 2000, STAR0602, and others.

Stay ahead with the most recent pipeline outlook for Human papillomavirus (HPV) Associated Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Human papillomavirus (HPV) Associated Cancer Treatment Drugs- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Human papillomavirus (HPV) Associated Cancer Emerging Drugs Profile
• STP909: Sirnaomics Inc
STP909 comprises siRNA targeting human papillomavirus (HPV) sequences formulated with our PNP delivery platform for intravenous and topical administration. Company developing STP909 as a prophylactic vaccine for prevention of cervical cancer and other disease caused by HPV.

• RTX-321: Rubius Therapeutics
RTX-321 is an allogeneic, off-the-shelf aAPC therapy product candidate that is engineered to induce a tumor-specific immune response by expanding antigen-specific T cells. RTX-321 expresses hundreds of thousands of copies of an HPV peptide antigen bound to major histocompatibility complex (MHC) class I proteins, the costimulatory molecule 4-1BBL and the cytokine IL-12 on the cell surface to mimic human T cell-APC interactions.

• BVAC-C: Cellid Co Ltd
BVAC-C uses HPV type 16/18's carcinogen gene, E6/E7's recombination gene as antigen to apply on cervical cancer, head and neck cancer, anal cancer, and sex organ cancer caused by HPV infection. CeliVax-based pipeline, BVAC-C, completed phase-I clinical trial to check safety and it is currently undergoing phase-II clinical trial to check effectiveness.

• GX-188E: Genexine Inc
GX-188E is a DNA therapeutic vaccine fused with encoding both E6 and E7 antigens as well as the extracellular domain of Flt3L to target and activate dendritic cells. GX-188E has ability to induce a tumor-specific CD8+ immune response and functional activity to eliminate target cells against high-grade cervical intra-epithelial neoplasms (CIN3, carcinoma in-situ). A phase 1b/2 clinical trial for the cervical cancer patients to evaluate safety, tolerability and efficacy is currently ongoing.

• ITI-2000: Immunomic Therapeutics Inc
ITI-2000 provides an UNITE platform address for HPV+ cancers. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product. ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers.

The Human papillomavirus (HPV) Associated Cancer Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Human papillomavirus (HPV) Associated Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Human papillomavirus (HPV) Associated Cancer Treatment.
• Human papillomavirus (HPV) Associated Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Human papillomavirus (HPV) Associated Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Human papillomavirus (HPV) Associated Cancer market

Explore groundbreaking therapies and clinical trials in the Human papillomavirus (HPV) Associated Cancer Pipeline. Access DelveInsight's detailed report now! @ New Human papillomavirus (HPV) Associated Cancer Drugs- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Human papillomavirus (HPV) Associated Cancer Companies
Turnstone Biologics, Advaxis, AstraZeneca, VLP The Vaccines Company SL, Voltron Therapeutics Inc, Rubius Therapeutics, Inovio Pharmaceuticals, Bristol-Myers Squibb, Precigen Inc, Privo Technologies, ViciniVax BV, Avalia Immunotherapies, BlueSky Immunotherapies, Cellid Co Ltd, Cue Biopharma, Cullinan Oncology, Genexine, EyeGene, Hookipa Pharma, Immunomic Therapeutics, ISA Pharmaceuticals BV, SQZ Biotechnologies and others.

Human papillomavirus (HPV) Associated Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous

Human papillomavirus (HPV) Associated Cancer Products have been categorized under various Molecule types such as
• Small molecule
• Gene Therapy
• Cell Therapy
• Immunotherapy

Unveil the future of Human papillomavirus (HPV) Associated Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Human papillomavirus (HPV) Associated Cancer Market Drivers and Barriers- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Human papillomavirus (HPV) Associated Cancer Pipeline Report
• Coverage- Global
• Human papillomavirus (HPV) Associated Cancer Companies- Turnstone Biologics, Advaxis, AstraZeneca, VLP The Vaccines Company SL, Voltron Therapeutics Inc, Rubius Therapeutics, Inovio Pharmaceuticals, Bristol-Myers Squibb, Precigen Inc, Privo Technologies, ViciniVax BV, Avalia Immunotherapies, BlueSky Immunotherapies, Cellid Co Ltd, Cue Biopharma, Cullinan Oncology, Genexine, EyeGene, Hookipa Pharma, Immunomic Therapeutics, ISA Pharmaceuticals BV, SQZ Biotechnologies and others.
• Human papillomavirus (HPV) Associated Cancer Pipeline Therapies- Aldesleukin, MEDI0457, RO5217790, Pembrolizumab, INO-3107, CELLECTRATM 2000, STAR0602, and others.
• Human papillomavirus (HPV) Associated Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Human papillomavirus (HPV) Associated Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Human papillomavirus (HPV) Associated Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Human papillomavirus (HPV) Associated Cancer Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Human papillomavirus (HPV) Associated Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Human papillomavirus (HPV) Associated Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Axalimogene filolisbac: Advaxis
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. PRGN-2009: Precigen PII
12. Drug profiles in the detailed report.....
13. Mid Stage Products (Phase II)
14. HB-200: Hookipa Pharma Inc
15. Drug profiles in the detailed report.....
16. Early Stage Products (Phase I)
17. RTX 321: Rubius Therapeutics
18. Drug profiles in the detailed report.....
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report.....
22. Inactive Products
23. Human papillomavirus (HPV) Associated Cancer Key Companies
24. Human papillomavirus (HPV) Associated Cancer Key Products
25. Human papillomavirus (HPV) Associated Cancer - Unmet Needs
26. Human papillomavirus (HPV) Associated Cancer - Market Drivers and Barriers
27. Human papillomavirus (HPV) Associated Cancer - Future Perspectives and Conclusion
28. Human papillomavirus (HPV) Associated Cancer Analyst Views
29. Human papillomavirus (HPV) Associated Cancer Key Companies
30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.